MCK logo

MCKESSON CORP

MCKNYSE
πŸ† #148 by market capEarnings Nov 3US Equity
$855.33β–Ό $1.11 (βˆ’0.13%)
Live
πŸ””
Track MCK
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.1%
7dβ–Ό 4.1%
14dβ–Ό 4.9%
30dβ–Ό 4.4%
ytdβ–² 4.3%
1yβ–² 12.2%
🏦Market Cap
$100.14B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+12.4%
Healthy
πŸ“ŠGross Margin
3.6%
Thin
πŸ’΅FCF Margin
1.5%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$850.08 – $868.11
52-Week Range
$723.68 – $999.00
Volume
$3.73B
Avg Volume
$3.32B
Shares Outstanding
117.1M
Next Earnings
Oct 24, 2026

Fundamentals Snapshot

Annual Revenue
$403.43B
Last Q Revenue
$105.38B
P/E Ratio
22.8
P/S Ratio
0.2x
EPS (TTM)
$38.69
Dividend Yield
0.40%
Dilution (1yr)
βˆ’3.6%

Why Investors Own MCK

  • βœ“High-growth profile β€” revenue up -8.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 56% gross margin and 24% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MCK logo

MCKESSON CORP

MCK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$403.4Bβ–² +12.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.6%β–² +3.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$6.5Bβ–² +47.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5.4Bβ–² +3.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
119.2Mβ–Ό βˆ’3.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$6.5Bβ–Ό βˆ’$872M YoY
StockOtter Β· stockotter.space

About MCKESSON CORP

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$835.18
β–Ό βˆ’2.4% Downside
High Target$939.04
Low Target$766.57
Based on 20 analysts

Latest News & Updates